Chinese cell therapy company JW Therapeutics (Shanghai) Co., Ltd announced that it has raised a US$90 million series A found led by investors Temasek, Sequoia Capital China, and YuanMing Capital, a Beijing-based US dollar fund focusing on investments in pharmaceutical research and development, medical devices and services in both China and the U.S. Oriza Seed Capital, Yipu Capital, AVICT Global Holdings, and existing investors WuXi AppTec Group, and Juno Therapeutics, also participated in the round. JW Therapeutics is a clinical … Chinese Cell Therapy Firm JW Therapeutics Closes $90 Million Series A Financing appeared first on China Money Network.